

## **Glenmark gains FDA approval for new generic**

24 February 2016 | News | By BioSpectrum Bureau

### **Glenmark gains FDA approval for new generic**



Glenmark Pharmaceuticals USA (Glenmark) has been granted final approval by the United States Food and Drug Administration (US FDA) for Norgestimate and Ethinyl Estradiol Tablets USP, 0.18 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.25 mg/0.025 mg.

Glenmark's drug is the generic version of Ortho Tri-Cyclen Lo Tablets of Janssen Pharmaceuticals.

According to IMS Health sales data for the 12 month period ending December 2015, the Ortho Tri-Cyclen Lo Tablets market achieved annual sales of approximately \$503.9 million.

Glenmark's current portfolio consists of 107 products authorized for distribution in the US marketplace and 62 ANDA's pending approval with the FDA.